Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRBW5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,325
Award facts
- Contract value 100% obligated
- $12,325.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on January 5, 2026, for EXPAREL 266 mg/20 mL vials valued at $12,325.41. The award represents a firm fixed-price delivery order under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which DMS Pharmaceutical Group holds as a prime vendor contractor. EXPAREL is a liposomal bupivacaine formulation used for surgical anesthesia and post-operative pain management, reflecting the company's role in supplying specialty pharmaceutical products to support Department of Defense healthcare operations. No set-aside designation was applied to this award, indicating the contractor competed on an unrestricted basis. The delivery order has an ultimate completion date of January 27, 2026, with performance to occur at the company's Park Ridge, Illinois facility.
This delivery order is issued under the broader PPV-G GEN V acquisition strategy, a $30.3 billion government-wide pharmaceutical supply initiative that establishes multiple regional prime vendor contractors to provide comprehensive pharmaceutical support to military healthcare facilities worldwide. DMS Pharmaceutical Group's prime vendor contract, awarded November 13, 2025, carries a $499.99 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The company's demonstrated federal contracting history and specialized pharmaceutical portfolio position it as a critical supplier within the Department of Defense's medical supply chain, enabling it to fulfill diverse and specialized pharmaceutical requirements across military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FRBW5?
SPE2DR26FRBW5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FRBW5 worth?
The government has obligated $12,325 on SPE2DR26FRBW5.
Is contract SPE2DR26FRBW5 an order under another contract?
Yes. SPE2DR26FRBW5 is a delivery order under SPE2DR25D9206, an indefinite delivery contract.
Was contract SPE2DR26FRBW5 competed?
The extent of competition for SPE2DR26FRBW5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award